Facilitating partnerships in drug discovery research
with a unique protected, open-innovation framework
Double-Blinded Drug Discovery (DBD2)

The mission of LIMR Chemical Genomics Center (LCGC) is to accelerate medicinal discovery within a new translational-research framework for public-private partnering. Double-Blinded Drug Discovery (DBD2), connects university and pharma scientists in a totally new way to validate 'druggability' of innovative cell-signaling targets while all intellectual property (IP) stays thoroughly protected. Productive collaborations are catalyzed that measurably accelerate technology transfer and commercialization of first-in-class medicines. University and pharmaceutical company scientists are invited to join the growing DBD2 Consortium.

LCGC in the News